Osteoporosis and other degenerative bone disease treatment strategies regularly employ bisphosphonates, hormone replacement therapy (HRT), selective oestrogen receptor modulators (SERMs), parathyroid hormone (PTH) analogues, or receptor activator of nuclear factor-kappa B ligand (RANKL) inhibitors (Table 1). This evidence concerns the gene TNFSF11 and osteoporosis.